RETA-MAX-16
Retatrutide|16 mg × 10 Vials
A research product containing retatrutide, an investigational molecule being studied for its activity across the GIP, GLP-1, and glucagon receptor pathways.
Each vial contains 16 mg, with 10 vials per kit, providing a total labeled quantity of 160 mg. Designed for qualified research and laboratory applications, RETA-MAX-16 provides researchers with a clearly identified retatrutide product format suitable for controlled experimental workflows.
Product Highlights
About Retatrutide
Retatrutide (LY3437943) is an investigational molecule developed by Eli Lilly and studied for its activity at three hormone receptors: GIP, GLP-1, and glucagon.
This multi-receptor activity distinguishes retatrutide from compounds that act primarily through a single receptor pathway. Researchers are investigating how simultaneous activity across these pathways influences metabolic and physiological processes.
Clinical research has evaluated retatrutide in areas including obesity, overweight, type 2 diabetes, and several obesity-related conditions.
Retatrutide remains an investigational compound and should not be represented as an approved therapeutic product or as an established treatment for any medical condition.
RETA-MAX-16 is therefore presented as an investigational research compound for qualified laboratory applications, rather than as an approved therapeutic product.
Product Specifications
| PRODUCT NAME | RETA-MAX-16 |
| COMPOUND | Retatrutide |
| ALTERNATIVE IDENTIFIER | LY3437943 |
| QUANTITY PER VIAL | 16 mg |
| NUMBER OF VIALS | 10 |
| TOTAL QUANTITY | 160 mg |
| PRODUCT TYPE | Investigational Research Compound |
| MOLECULAR CLASSIFICATION | GIP / GLP-1 / Glucagon Triple Agonist |
| PHYSICAL FORM | Verify with manufacturer |
| INTENDED APPLICATION | Laboratory / Research Use |
| PACKAGING | 10-vial kit |
| BRAND | Maxtreme Pharma |
Note: The product image establishes the product name, compound, vial strength, and kit quantity. Physical form, purity, formulation, and analytical specifications should be confirmed using the applicable manufacturer documentation or CoA.
Research Applications
Retatrutide is being investigated because of its activity across the GIP, GLP-1, and glucagon receptor pathways. Research areas may include:
Researchers can use controlled experimental models to investigate the biological characteristics and receptor activity of retatrutide.
These research areas describe scientific investigation only and do not constitute approved medical indications or recommendations for human use.
Retatrutide Research Profile
Retatrutide is notable for its triple receptor activity, acting at the GIP, GLP-1, and glucagon receptors within a single molecule.
This mechanism has made the compound an important subject of metabolic research, with studies examining its effects on body weight, glucose regulation, metabolic parameters, and other physiological outcomes.
Clinical development has progressed into advanced-stage research, but investigational findings should be distinguished from regulatory approval and should not be interpreted as establishing that an independently supplied product has the same quality, formulation, safety profile, or clinical characteristics as material used in controlled clinical trials.
Quality & Packaging
The RETA-MAX-16 kit contains 10 individually packaged vials, with 16 mg of labeled retatrutide per vial, providing a total labeled quantity of 160 mg per kit.
The packaging clearly identifies the product as RETA-MAX-16 / Retatrutide and specifies the individual vial strength and total kit configuration.
For professional research procurement, researchers should verify the applicable:
- Certificate of Analysis (CoA)
- Batch / lot number
- Compound identity
- Purity specification
- Assay results
- Analytical testing
- Formulation information
- Storage requirements
Batch-specific documentation is particularly important when working with investigational compounds.
Storage & Handling
Store and handle RETA-MAX-16 according to the manufacturer's batch-specific technical documentation and Certificate of Analysis.
The stability of peptide-based research materials may depend on factors including temperature, moisture, light exposure, formulation, and handling conditions.
Researchers should follow the manufacturer's documented storage and handling requirements rather than relying on generic recommendations.
Appropriate laboratory procedures and applicable safety protocols should be followed when handling experimental research materials.
RETA-MAX-16 contains retatrutide, an investigational compound.
Retatrutide should not be represented as an approved medication or as a treatment for obesity, diabetes, weight loss, or any other medical condition.
This product is intended only for qualified research and laboratory applications, subject to applicable laws, regulations, institutional requirements, and laboratory safety procedures.
No claim is made that this specific product is safe or effective for the diagnosis, treatment, cure, or prevention of any disease or medical condition.
Not for human consumption or self-administration.
Frequently Asked Questions
RETA-MAX-16 is a research product containing retatrutide (LY3437943), an investigational molecule that acts on the GIP, GLP-1, and glucagon receptor pathways.
Each vial contains 16 mg according to the product packaging.
The kit contains 10 vials.
The kit contains 160 mg total, calculated as: 10 vials × 16 mg = 160 mg.
Retatrutide, also known as LY3437943, is an investigational triple receptor agonist that activates the GIP, GLP-1, and glucagon receptors.
Retatrutide is described as a triple agonist because the molecule has activity at three receptor targets: GIP, GLP-1, and glucagon.
Retatrutide has been investigated in areas including obesity, type 2 diabetes, glucose regulation, metabolic health, and cardiometabolic research. These research areas do not constitute approved medical applications.
Not exactly. Retatrutide should not simply be described as a “GLP-1.” It is a triple receptor agonist with activity at GIP, GLP-1, and glucagon receptors.
Retatrutide remains an investigational compound and should not be presented on your product page as an approved medication.
No. The product should be presented as For Research Use Only and not for human consumption or self-administration, subject to applicable laws and regulatory requirements.
Professional research customers should request the applicable Certificate of Analysis (CoA) and batch information, including identity, purity, assay, analytical testing, formulation, and storage information.